Effects of beta-1,3-D glucan on systemic bortezomib treated rat pancreas

Abstract

Bortezomib, selective inhibitor of the 26S proteasome, is used for treatment of some types of cancer and immunosuppressive therapies. B-1,3-(D)-glucan, a synthetic antioxidant is used complementary medical treatment for human. This study was conducted to investigate the effects of the antioxidant Beta-1,3-D glucan on rat pancreas treated with systemic bortezomib. In the study, 36 Sprague-Dawley adult male rats were divided into four groups: control (C), bortezomib (BZ), β-1, 3-D-glucan (BD) and bortezomib + β-1,3- (D) –glukan (BZ+BD). Each group was divided into two subgroups (48 or 72 hours), depending on the time of sacrification. After experiments, immunohistochemical, stereological and histopathological changes in all rat pancreatic tissues were examined. It was determined increased degenerative, vacuolated serous acini cells and inflammatory cell infiltrations in the groups of BZ and BZ+BG. In immunohistochemical analysis, densities of insulin positive cells were decreased in the groups of BZ and BZ+BG. Furthermore, in stereological mean volume of serous acinus analysis, significantly increases were detected in the groups of BZ and BZ+BG (p<0.05). BZ treatment had the detrimental effects on pancreas tissues. Also, administration of BG was insufficient to prevent injury induced by BZ treatment in the pancreas tissues.

Keywords

• Bortezomib
• Beta glucan
• pancreas
• İnsulin
• oxidative stress

References

1. Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S. Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects. Cancers (Basel). 2020; 12(9): 2540.
2. Otoda T, Takamura T, Misu H, Ota T, Murata S, Hayashi H. et al. Proteasome Dysfunction Mediates ObesityInduced Endoplasmic Reticulum Stress and Insulin Resistance in the Liver. Diabetes. 2013; 62.3: 811-824.
3. Yang X. Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium. Biomedicine & Pharmacotherapy 2012; 66: 607-611.
4. Stein ML, Groll M. Applied techniques for mining natural proteasome inhibitors. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 2014; 1843(1), 26-38.
5. Dai Y, Guo X, Yang C. Caponigro F. Effect of bortezomib on proliferation and apoptosis of myeloma cells by activating Wnt/beta-catenin signaling pathway. Oncol Lett. 2020; 20(2):1295-1299.
6. Yu S, Zheng L, Li Y, Li C, Ma C, Yu Y, et al. Causal co-expression method with module analysis to screen drugs with specific target. Gene. 2013; 518.1: 145-151.
7. Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int J Mol Sci. 2019; 22;20(6):1451.
8. Gelman, J. S., Sironi, J., Berezniuk, I., Dasgupta, S., Castro, L. M., Gozzo, Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. PLoS One. 2013; 8: e53263.

9. Schmidt N, Alloway RR, Walsh RC, et al. Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. Transplantation. 2012; 94: 352-361.
10. Mateos MV. How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events. Leukemia research. 2012; 36 Suppl 1: S35-43.
11. Narayanan S, Cai CY, Assaraf YG, Guo HQ, Cui Q, Wei L, Huang JJ, Ashby CR Jr, Chen ZS. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat. 2020;48:100663.
12. Weniger MA, Rizzatti EG, Pérez-Galán P, Liu D, Wang Q, Munson PJ, et al. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clinical Cancer Research, 2011; 17; 5101-5112.
13. Gonzalez A, Huerta-Salgado C, Orozco-Aguilar J, Aguirre F, Tacchi F, Simon F, Cabello-Verrugio C. Role of Oxidative Stress in Hepatic and Extrahepatic Dysfunctions during Nonalcoholic Fatty Liver Disease (NAFLD). Oxid Med Cell Longev. 2020;19:1617805.
14. Yaribeygi H, Sathyapalan T, Atkin SL, Sahebkar A. Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus. Oxid Med Cell Longev. 2020; 9;8609213.
15. Leung PS, Chan YC. Role of oxidative stress in pancreatic inflammation. Antioxidants & redox signaling. 2009; 11: 135-165.
16. Reuter S, Gupta SC, Chaturvedi MM, et al. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010; 49: 1603-1616.
17. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB, et al. Oxidative stress and diabetes: what can we learn about insulin resistance from antioxidant mutant mouse models? Free radical biology and medicine 2012; 52: 46-58.
18. Zhang P, Li T, Wu X, Nice EC, Huang C, Zhang Y. Oxidative stress and diabetes: antioxidative strategies. Front Med, 2020;14(5):583-600.
19. Poljsak B, Milisav I. The neglected significance of "antioxidative stress". Oxidative medicine and cellular longevity. 2012; 2012: 480895.
20. Jurczyńska E, Saczko J, Kulbacka J, Kawa-Rygielska J, Błazewicz J. et al. Beta-glucan as a natural anticancer agent. Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego. 2012; 33: 217-220.
21. Akaras N, Abuc OO, Koc K, Bal T, Geyikoglu F, Atilay H, Erol HS, Yigit S, Gul M. (1 3)-beta-d-glucan enhances the toxicity induced by Bortezomib in rat testis. J Food Biochem. 2020;44(3):13155.
22. Ozdemir S, Toplan S, Tanriverdi G, Sunamak O. The effects of beta-glucan on iron levels and lipid peroxidation in intra-abdominal sepsis in rats. General physiology and biophysics. 2011; 30: 138-144.
23. Albayrak Y, Halici Z, Odabasoglu F, Unal D, Keles ON, Malkoc I, et al. The effects of testosterone on intestinal ischemia/reperfusion in rats. Journal of Investigative Surgery 2011; 24: 283-291.
24. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. Journal of the National Cancer Institute 2006; 98: 1142-1157.
25. Patchen ML, D'alesandro MM, Brook I, Blakely WF, MacVittie TJ . Glucan: mechanisms involved in its" radioprotective" effect. Journal of leukocyte biology. 1987; 42: 95-105.
26. Tsiapali E, Whaley S, Kalbfleisch J, Ensley HE, Browder IW, Williams DL. Glucans exhibit weak antioxidant activity, but stimulate macrophage free radical activity. Free Radical Biology and Medicine. 2001; 30: 393-402.
27. Richardson PG. Assessment of Proteasome Inhibition for Extending Remissions I. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352: 2487-2498.
28. Gomez-Abuin G, Winquist E, Stadler WM, Pond G, Degendorfer P, Wright J, et al. A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Investigational new drugs. 2007; 25: 181-185.
29. Zhang P, Li T, Wu X, Nice EC, Huang C, Zhang Y. Oxidative stress and diabetes: antioxidative strategies. Front Med. 2020;14(5):583-600.
30. Pang L, Lian X, Liu H, Zhang Y, Li Q, Cai Y, Ma H, Yu X. Understanding Diabetic Neuropathy: Focus on Oxidative Stress. Oxid Med Cell Longev. 2020;9524635.
31. Luc K, Schramm-Luc A, Guzik TJ, Mikolajczyk TP. Oxidative stress and inflammatory markers in prediabetes and diabetes. J Physiol Pharmacol. 2019;70(6): 26402.
32. Elouni B, Salem CB, Zamy M, Sakhri J, Bouraoui K, Biour M. Bortezomib-induced acute pancreatitis. Journal of the Pancreas 2010; 11: 275-276.
33. Badalov N, Baradarian R, Iswara K, Li J, Steinberg W. Tenner S. Drug-induced acute pancreatitis: an evidencebased review. Clinical Gastroenterology and Hepatology. 2007; 5: 648-661.
34. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Experimental neurology. 2007; 204: 317-325.
35. Ding W-X, Ni H-M, Yin X-M. Absence of Bax switched MG132-induced apoptosis to non-apoptotic cell death that could be suppressed by transcriptional or translational inhibition. Apoptosis. 2007; 12: 2233-2244.
36. Carozzi VA, Renn CL, Bardini M, Fazio G, Chiorazzi A, Meregalli C, et al. Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse. PLoS One. 2013; 8: e72995.
37. Takamatsu H, Yamashita T, Kotani T, Sawazaki A, Okumura H, Nakao S, et al. Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma. International journal of hematology. 2010; 91: 903-906.
38. Bagni M, Romano N, Finoia MG, Abelli L, Scapigliati G, Tiscar PG, et al. Short-and long-term effects of a dietary yeast β-glucan (Macrogard) and alginic acid (Ergosan) preparation on immune response in sea bass. Fish & Shellfish Immunology. 2005; 18: 311-325.
39. Parlak SN, Tatar A, Keles ON, Selli J, Can I, Unal B. Effects of menopause and diabetes on the rat parotid glands: A histopathological and stereological study. Int J Med Sci Public Health. 2014; 3: 749.
40. Sabri A, Hughie HH, Lucchesi PA. Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxidants and Redox Signaling. 2003; 5: 731-740.